S&P 500   3,310.11 (+1.19%)
DOW   26,659.11 (+0.52%)
QQQ   276.39 (+1.75%)
AAPL   115.32 (+3.71%)
MSFT   204.72 (+1.01%)
FB   280.83 (+4.92%)
GOOGL   1,556.88 (+3.05%)
AMZN   3,211.01 (+1.52%)
TSLA   410.83 (+1.18%)
NVDA   520.96 (+3.14%)
BABA   312.56 (+1.50%)
CGC   18.78 (+2.40%)
GE   7.37 (-0.67%)
MU   50.48 (+0.96%)
AMD   78.02 (+2.12%)
T   26.76 (+0.98%)
F   7.90 (+2.60%)
ACB   4.09 (+6.79%)
GILD   58.53 (-0.32%)
NFLX   504.21 (+3.70%)
NIO   31.99 (+16.28%)
BA   148.29 (+0.10%)
DIS   121.54 (+2.59%)
S&P 500   3,310.11 (+1.19%)
DOW   26,659.11 (+0.52%)
QQQ   276.39 (+1.75%)
AAPL   115.32 (+3.71%)
MSFT   204.72 (+1.01%)
FB   280.83 (+4.92%)
GOOGL   1,556.88 (+3.05%)
AMZN   3,211.01 (+1.52%)
TSLA   410.83 (+1.18%)
NVDA   520.96 (+3.14%)
BABA   312.56 (+1.50%)
CGC   18.78 (+2.40%)
GE   7.37 (-0.67%)
MU   50.48 (+0.96%)
AMD   78.02 (+2.12%)
T   26.76 (+0.98%)
F   7.90 (+2.60%)
ACB   4.09 (+6.79%)
GILD   58.53 (-0.32%)
NFLX   504.21 (+3.70%)
NIO   31.99 (+16.28%)
BA   148.29 (+0.10%)
DIS   121.54 (+2.59%)
S&P 500   3,310.11 (+1.19%)
DOW   26,659.11 (+0.52%)
QQQ   276.39 (+1.75%)
AAPL   115.32 (+3.71%)
MSFT   204.72 (+1.01%)
FB   280.83 (+4.92%)
GOOGL   1,556.88 (+3.05%)
AMZN   3,211.01 (+1.52%)
TSLA   410.83 (+1.18%)
NVDA   520.96 (+3.14%)
BABA   312.56 (+1.50%)
CGC   18.78 (+2.40%)
GE   7.37 (-0.67%)
MU   50.48 (+0.96%)
AMD   78.02 (+2.12%)
T   26.76 (+0.98%)
F   7.90 (+2.60%)
ACB   4.09 (+6.79%)
GILD   58.53 (-0.32%)
NFLX   504.21 (+3.70%)
NIO   31.99 (+16.28%)
BA   148.29 (+0.10%)
DIS   121.54 (+2.59%)
S&P 500   3,310.11 (+1.19%)
DOW   26,659.11 (+0.52%)
QQQ   276.39 (+1.75%)
AAPL   115.32 (+3.71%)
MSFT   204.72 (+1.01%)
FB   280.83 (+4.92%)
GOOGL   1,556.88 (+3.05%)
AMZN   3,211.01 (+1.52%)
TSLA   410.83 (+1.18%)
NVDA   520.96 (+3.14%)
BABA   312.56 (+1.50%)
CGC   18.78 (+2.40%)
GE   7.37 (-0.67%)
MU   50.48 (+0.96%)
AMD   78.02 (+2.12%)
T   26.76 (+0.98%)
F   7.90 (+2.60%)
ACB   4.09 (+6.79%)
GILD   58.53 (-0.32%)
NFLX   504.21 (+3.70%)
NIO   31.99 (+16.28%)
BA   148.29 (+0.10%)
DIS   121.54 (+2.59%)
Log in
NASDAQ:EPZM

Epizyme Stock Forecast, Price & News

$12.62
+0.20 (+1.61 %)
(As of 10/29/2020 12:00 AM ET)
Add
Compare
Today's Range
$12.19
Now: $12.62
$12.81
50-Day Range
$11.03
MA: $12.56
$13.77
52-Week Range
$10.70
Now: $12.62
$27.82
Volume686,875 shs
Average Volume1.04 million shs
Market Capitalization$1.28 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.82
Epizyme, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma epithelioid sarcoma in the United States. It also develops Tazemetostat in combination with rituximab in patients with relapsed and refractory follicular lymphoma; R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma (DLBCL); and PARP inhibitor in patients with platinum-resistant solid tumors, such as small-cell lung cancer, triple-negative breast cancer, and ovarian cancer. In addition, it develops Tazemetostat in patients with castration-resistant prostate cancer; and pediatrics with INI1-negative tumors. Further, the company develops pinometostat for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; PRMT5 inhibitor for patients with solid tumors and blood cancers; and PRMT1 inhibitor for solid tumors and DLBCL. Epizyme, Inc. has collaboration agreements with Celgene Corporation; Genentech Inc.; Glaxo Group Limited; Boehringer Ingelheim International GmbH; Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; and Eisai Co. Ltd. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Read More
Epizyme logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.56 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EPZM
CUSIPN/A
Phone617-229-5872
Employees203

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$23.80 million
Book Value$3.22 per share

Profitability

Net Income$-170,290,000.00
Net Margins-1,459.72%

Miscellaneous

Market Cap$1.28 billion
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$12.62
+0.20 (+1.61 %)
(As of 10/29/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EPZM News and Ratings via Email

Sign-up to receive the latest news and ratings for EPZM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Epizyme (NASDAQ:EPZM) Frequently Asked Questions

How has Epizyme's stock price been impacted by Coronavirus (COVID-19)?

Epizyme's stock was trading at $18.46 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, EPZM stock has decreased by 31.6% and is now trading at $12.62.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Epizyme?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Epizyme in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Epizyme
.

When is Epizyme's next earnings date?

Epizyme is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Epizyme
.

How were Epizyme's earnings last quarter?

Epizyme, Inc. (NASDAQ:EPZM) released its earnings results on Tuesday, August, 4th. The biopharmaceutical company reported ($0.58) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.56) by $0.02. The biopharmaceutical company earned $2.47 million during the quarter, compared to analysts' expectations of $4.67 million. Epizyme had a negative return on equity of 72.65% and a negative net margin of 1,459.72%.
View Epizyme's earnings history
.

What price target have analysts set for EPZM?

8 Wall Street analysts have issued twelve-month price objectives for Epizyme's shares. Their forecasts range from $16.00 to $36.00. On average, they anticipate Epizyme's stock price to reach $29.00 in the next year. This suggests a possible upside of 129.8% from the stock's current price.
View analysts' price targets for Epizyme
.

Who are some of Epizyme's key competitors?

What other stocks do shareholders of Epizyme own?

Who are Epizyme's key executives?

Epizyme's management team includes the following people:
  • Mr. Robert B. Bazemore Jr., Pres, CEO, Sec. & Director (Age 52, Pay $1.01M)
  • Mr. Paolo Tombesi, Chief Financial Officer (Age 56, Pay $628.41k)
  • Mr. Matthew E. Ros, Chief Strategy & Bus. Officer (Age 53, Pay $644.06k)
  • Dr. Shefali Agarwal M.D., MPH, Chief Medical Officer (Age 46, Pay $737.27k)
  • Dr. H. Robert Horvitz, Co-Founder & Chairman of the Scientific Advisory Board
  • Dr. Yi Zhang, Scientific Co-Founder & Member of The Scientific Advisory Board
  • Mr. Joseph Beaulieu, Controller, Treasurer & Principal Accounting Officer (Age 39)
  • Dr. Jeffery L. Kutok, Chief Scientific Officer (Age 53)
  • Jason Fredette, VP of Investor Relations
  • Mr. John F. Weidenbruch, Gen. Counsel (Age 59)

What is Epizyme's stock symbol?

Epizyme trades on the NASDAQ under the ticker symbol "EPZM."

Who are Epizyme's major shareholders?

Epizyme's stock is owned by a variety of institutional and retail investors. Top institutional investors include Candriam Luxembourg S.C.A. (0.36%), North Star Investment Management Corp. (0.12%), Dupont Capital Management Corp (0.03%), Wedbush Securities Inc. (0.03%), DekaBank Deutsche Girozentrale (0.02%) and Altfest L J & Co. Inc. (0.02%). Company insiders that own Epizyme stock include David M Mott, Joseph Beaulieu, Matthew Ros, Paolo Tombesi, Robert B Bazemore and Shefali Agarwal.
View institutional ownership trends for Epizyme
.

Which major investors are selling Epizyme stock?

EPZM stock was sold by a variety of institutional investors in the last quarter, including Dupont Capital Management Corp. Company insiders that have sold Epizyme company stock in the last year include Joseph Beaulieu, Matthew Ros, Paolo Tombesi, Robert B Bazemore, and Shefali Agarwal.
View insider buying and selling activity for Epizyme
.

Which major investors are buying Epizyme stock?

EPZM stock was bought by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., DekaBank Deutsche Girozentrale, North Star Investment Management Corp., Pacer Advisors Inc., Nisa Investment Advisors LLC, Altfest L J & Co. Inc., and Wedbush Securities Inc..
View insider buying and selling activity for Epizyme
.

How do I buy shares of Epizyme?

Shares of EPZM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Epizyme's stock price today?

One share of EPZM stock can currently be purchased for approximately $12.62.

How big of a company is Epizyme?

Epizyme has a market capitalization of $1.28 billion and generates $23.80 million in revenue each year. The biopharmaceutical company earns $-170,290,000.00 in net income (profit) each year or ($1.93) on an earnings per share basis. Epizyme employs 203 workers across the globe.

What is Epizyme's official website?

The official website for Epizyme is www.epizyme.com.

How can I contact Epizyme?

Epizyme's mailing address is 400 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-229-5872 or via email at [email protected]

This page was last updated on 10/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.